Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Veterinary Vertex

Veterinary Vertex artwork

Gut Check: Why Oral Fecal Transplants Fell Short for Tylosin-Responsive Dogs

Oct 30, 202618 minAudio

Send us Fan Mail Dogs with chronic enteropathy can make even seasoned clinicians feel stuck: antibiotics help, symptoms fade, then everything flares the moment treatment stops. We sit down with Drs. Moshen Hanifeh and Jan Suchodolski to unpack their placebo controlled, double blind trial on oral fecal microbiota transplantation (FMT) in dogs with tylosin responsive enteropathy, a subgroup where relapse after tylosin is a familiar and frustrating pattern. If you’ve been wondering whether “poop capsules” are ready for prime time in veterinary gastroenterology, this conversation gives you the clearest real world framework we’ve heard. We get specific about what oral FMT actually is, how lyophilized donor feces can be packaged into capsules, and why oral dosing limits may matter in chronic GI disease. Then we dig into the data story clinicians wrestle with every day: measurable microbiome changes, subtle movement in biomarkers, and still no clear, meaningful clinical signal compared with placebo. Along the way, we explore why chronic enteropathy is heterogeneous, how the dysbiosis index functions as a severity marker, and why inflammation markers and dysbiosis do not always track together. We also translate the findings into practical next steps for treating dogs with TRE right now: stick with therapies that work, prioritize diet management and a thoughtful diagnostic workup, and view oral FMT as promising but not yet a routine standalone option. To close, we map the research roadmap: larger trials, longer follow up, patient stratification by baseline dysbiosis, and comparisons of oral versus enema delivery or combined protocols. Subscribe for more evidence based veterinary medicine conversations, share this episode with a colleague who treats chronic GI cases, and leave a rating and review to help more listeners find the show. JAVMA article: https://doi.org/10.2460/javma.26.03.0178 INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ®? JAVMA ®: https://avma.org/JAVMAAuthors AJVR ®: https://avma.org/AJVRAuthors FOLLOW US: JAVMA ®: Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ®: Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_03You show up for pets every day. It's because care is your calling. And it's ours too. We know it's what drives you to make a difference in the health and well-being of every pet. That's because at Doetis, hundreds of veterinarians are part of our team too, working with you to provide science-backed medicines, technology, and practical support to help elevate your standard of care. Learn more at care is your calling.com.

Lisa FortierWelcome to Epic Award-winning Veterinary Vertex, the AVMA Journal podcast, where we delve into behind-the-scene look with manuscript authors. I'm editor-in-chief Lisa Fortier, joined by Associate Editor Sarah Wright. Today we're discussing microbiome changes with limited clinical effects following oral fecal microbiota transplantation in dogs with chronic enteropathy, responsive to talysin with Moshin Hanafe, and Jan Shukoldowski. Thank you for joining us.

SPEAKER_02Thank you so much for inviting us. It's a great pleasure to be here. And we are so excited to discuss our study. Same here.

Lisa FortierAll right, let's dive in. Moshin, for listeners unfamiliar with the condition, what is tylosin responsive enteropathy and why did you want to test fecomycobiotic transplantation specifically in dogs with this condition?

SPEAKER_02Actually, uh chronic enteropathy, a responsive tylosin, is a type of chronic enteropathy in dogs. Uh in dogs uh that they have chronic GI signs like diarrhea or vomiting, but they improve when we start tylosin treatment. But the problem is that when we stop tylosin treatment, many of them relapse. And from clinical perspective, this is concerning for two reasons.

SPEAKER_02First, repeated antibiotic treatment can increase concerns about antimicrobial resistance, and second, antibiotic can alter intestinal microbiota and contribute to dysbiosis and sometimes for a quite long time. So that led us to ask ourselves whether we could restore a healthier microbiome instead of using repeatedly antibiotic to suppress it.

SPEAKER_02So FMT came to our mind, so fecal microbiota transplantation or FMT insure uh transfers a broad community of microorganisms from a carefully screened healthy donor. So our hope was that after stopping thylosin treatment in dogs with TRE, uh FMT might help us to maintain remesion and also to help us to reduce the repeated use of antibiotic.

SPEAKER_02That was really the questions we wanted to answer.

Sarah WrightFecal transplants get a lot of buzz right now. What made this the right population to study it in? And what were you hoping to see?

SPEAKER_01Yeah, so I think maybe I have to take a step back. That's originally when you look at chronic anthropathy, it develops a lot our understanding over the last few, you know, five to ten years. And originally we always thought we have this specific disease like dysbiosis, right? Well, we have dysbiosis. That's why a lot of those animals respond to antibiotics. And so kind of logically, it would make sense if somebody responds to antibiotic, they're probably also gonna respond to a different form of modulation, right? So that was kind of the background behind it. Also, important probably to mention that this study was designed like probably like five or seven years ago, right?

SPEAKER_01And since then, we kind of as bad understands. We're gonna probably discuss it a bit later too, but understanding the pataphysiometry of chronic anthropathy. And so I think it kind of makes sense in this one, but in the future, we're probably it's not like a specific disease that we're targeting here. It's really trying to module the intestinal environment independent of how they respond. But it's kind of an important feature. But so there was logically thing, but now we're also understanding that many of those animals have chronic GI disease, and that's why I think FMT, you know, is gonna be this adjunct therapy, but unlikely to be the only treatment that they will respond to.

Lisa FortierYeah, I like that background, Jan. Uh, can you walk us through oral FMT? How is it prepared and how is it administered?

SPEAKER_01So, generally, oral FMT, the beauty of FMT is it's actually a very simple procedure that theoretically many can do in their own practice in the future. So, so there's also maybe we're gonna discuss a little bit later how we're gonna probably move on to the future, but there's an oral FMT and Reclin FMT, right? Oral FMT is generally that we're trying to you know package feces. So in this study it was Lyophilized feces with a lyophyzer that is freeze dryer that ultimately then we add um some how to call it caraprotectant to it. But the research is other devices where we can actually take fresh feces and pack it into capsule, which is a little more messy.

SPEAKER_01But in general, we just take really feces and you know put it into capsules and administer orally. So the advantage is it's more convenient to some degree for the owners, right? Um, the disadvantage is that when you compare this to rectal anemone, is that with all FMT, we have a limited amount of dosage we can give per day, right? And so this is important also when we discuss later what disease is the best response to FMT. In chronic GI disease, that's a limited factor.

Sarah WrightMostin, you got a really sophisticated study design. Why was a double-blind placebo-controlled design so important here, given how variable GI conditions can already be from dog to dog?

SPEAKER_02That's an excellent question. Uh, actually, many of our clinical outcomes uh were assessed by both the owners and also the investigator. So having randomized double-blind placebo control trial was very crucial in our study. So neither the owners nor the investigator knew what kind of treatment each dog received. So this reduced the risk, uh risk that expectation could influence the those assessments, right?

SPEAKER_02Uh uh another important point in our study was that we saw some improvement in the microbiome in both groups. So without the placebo group, uh we might have incorrectly uh attributed all those changes to FMT. So that's why our design uh was give us a great uh confidence to interpret our results, and I think it was one of the major uh threats of our study.

Lisa FortierYeah, it's really great. We always uh placebo is so much stronger than we think it is.

SPEAKER_02Absolutely, yeah.

Lisa FortierYeah, and and uh Jan, maybe from you then, uh something you can't really uh get a placebo effect on are different biomarkers. You had a dysbiosis index, bile acids, cow protectin, which I'd never heard of before. I'm an equine orthopedic surgeon, I don't know what that is, uh, and many more. Uh why did you cast such a wide net and and what would you what would you carry forward into the next study?

SPEAKER_01Well, I think the more we understand the underlying GI disease, we also know that it's a very heterogeneous disease. So chronic GI disease is not just one bucket where you can say, this is one mark, it's gonna tell me. Because the GI type is a long organ, right? And we have inflammation, we have dysbiosis. Dysbiosis leads ultimately to you know microbial functional changes, biology, metabolism. And so I think we also understand that every patient has different um, what do you call it? It's an agraded disease, right? So chronic GI disease happens on a gradient.

SPEAKER_01So not every patient is gonna have the same severity. So a can contact them, for example, is an inflammation marker. The inflammation happens also. Some patients have strong inflammation, some of them have mild inflammation. We also have shown recently that dysbiosis, for example, is also only present in a subset of animals. But those that have dysbiosis usually are those that have more severe GI dysfunction. The dysbiosis becomes this biomarker of current GI dysfunction, you know, the micro responds to mild absorption, you know, there are suddenly some MLs that increase carbohydrates and things like that.

SPEAKER_01So it's a two-prong approach. First of all, we do also understand better GI disease. And so we understand it's heterogeneous, so you cannot just focus on one single marker. Second of all, is that we're also understanding now that dysbiosis is a severity biomarker. It probably reflects the more severe underlying GI condition, right? And so with time, they co-correlate. But in research studies, we still want to, you know, the more data we generate, and the more confident we come that we also understand some of those co-correlate. For example, dysbiosis index co-orrelates with balses metabolism. So maybe in the future you don't have to measure all of them.

SPEAKER_01But on health inflammation is not always hand in hand with dysbiosis. So the better we understand each part of the GI tract, like any other organ system, measuring from different sides, the better we can create those panel of biomarkers that hopefully it's going to be in the future. The best diagnostic biomarker, you know, severity assessment mark and also predictive marker. So that's the reason.

Sarah WrightVery pool. I find biomarker research so fascinating.

SPEAKER_01It's also challenging.

Sarah WrightYes, that's too. That's too. Jan, Bacalibacterium increased more and the FMT group specifically. Does that suggest FMT is doing something at the microbiome level, even without a clear clinical signal?

SPEAKER_01Overall, yes. So I think when you look at the whole microbiome and dysbiosis index, that the index predicts a total shift in a microbiome. And so we can see that a total microbiome didn't really, you know, improve drastically. So there was a small numerical decrease. But you can see that some bacteria improve, but not all of them. And so each of those bacteria do a little bit something differently. So for example, Fecali bacterium is known to be like a short-in-fatty acid producer. But otherwise, because they didn't really improve, like anonis, with this biasic convert, and it's the strongest biomarker for dysbiosis, didn't really improve, right?

SPEAKER_01So that's why the total microbiome didn't change. So yes, we got some improvement in the microbiome, but overall not sufficient, probably to also improve the total clinical science.

Lisa FortierI thought it was interesting that so many of the biomarkers moved in the similar direction across both groups. What was your reaction to that? Is that something about these dogs or placebo effect? What do you think?

SPEAKER_01Well, I think overall we we saw smaller changes, right, in both groups across, right? And with a little bit numerical, bigger change in FMT groups. So FMP clearly did improve some of those biomarkers to some degree, right? But the threshold probably was not sufficient to really have a long-lasting effect. But on the other flip studies that we also see, and that is consistent with other data we have now generating, is that many dogs with chronic GI disease usually stay persistently abnormal. So I think that you know we need to realize more and more that chronic GI disease in many patients is probably a long, long-term, even not even like long disease, if that makes sense, right?

SPEAKER_01So, you know, those management we can help with them, but if the biomarkers stay abnormal, that really indicates that they are chronic abnormal. That's why many of those biomarkers co-correlate, right? So each of them tells a little bit different, but overall the OMO GI function does not normalize in those patients.

Sarah WrightYou shared a lot of really great information today. And now I want to try to boil it down. So one really important take-home point for the veterinarian. For a veterinarian treating a dog with tylesin responsive enteropathy today, what's the practical takeaway from this study? Is FMT worth trying or is it premature?

SPEAKER_02I think the practical takeaway is that FMT is promising. Uh oral FMT is promising, but I think this oral protocol is not ready to be used as a routine treatment for dogs with TRE. Uh actually, we saw some biological changes uh in the microbiome, but they didn't translate into uh meaningful and clear clinical effects compared with placebo.

SPEAKER_02Uh for now I would continue with the treatments that we know are effective, including tyosine, we needed diet management and also investigating other causes of chronic enterpathy. Uh and I think we we need larger studies with larger number of dogs to get to the point that we know whether FMT is can be used, for example, as a loan treatment, or do we need to use it as an adjunct treatment, for example, at the same time with diet or thylosine?

Lisa FortierYeah, maybe to wrap up from both of you, uh it I mean there are some indicators that it's moving the needle a little bit. So, what might the next studies look like? Optimized treatment, the donor dog, obviously, as Michelle just said, more dogs. Uh but is it dosing timing from each of you? What might be the next step towards optimization?

SPEAKER_01Yeah, I mean, from my from my point of view, we need to, you know, we're moving into multimodal approaches. That's number one, right? So and so, for example, this study, we didn't really do extensive diet trials because again, there was a study that was initiated like many years ago where diet trials was not yet so intuitive. So, usually we recommend now to much more focus on the dietary trial chips or more, right? So this was missing in this study. So for me, diet is going to be always the basis of every every growth. And then we need to try you know different diet types. And then FMT can be the junk therapy, right?

SPEAKER_01So I think that's number one. Number two is that maybe the dose, oral dose, as I mentioned before, is just limiting because obviously we cannot give too many capsules, you know, in dogs. Like, you know, there's a lot of confusion a little bit in compared to humans, you know. In humans, for example, where oral FMT has great success is truly for colistum difficile infection, right? But there it's almost like a bolus getting. You want to give a lot of capsules over one or two days because you really want to give this, you know, you want to kind of push out clostum difficile. In chronic GI disease, we know that those biomarkers that stay abnormal indicate in the cactus anoma chronically.

SPEAKER_01So we know it really is gonna be a long, long treatment. And so enemies, for example, is one where we have a lot of success, right? But even with enemas, we sometimes have to repeat it, you know, uh every few months and things like that. So I think for me, probably the combination is gonna be maybe some of those animals are gonna have to get started with an enema, and then in between all FMT. So I think the future is gonna be diet, diet, diet. And then if there's still need for additional treatments, FMT will be probably individualized. And I think that's an important concept.

SPEAKER_01It's not gonna be an algorithm. We need to take every patient into consideration what's the base level, severity of this biosis. We know that severity of this bios is strong, that we need to probably be much more aggressive with treatment. So I think those are the optimizations we need. But also realize now with many studies is that individualization is a very important concept. I think.

Lisa FortierYeah, very good points. How about you, Mo Shane?

SPEAKER_02Uh actually, in my opinion, the first priority is larger studies with larger sample size, because our study sample size was not enough to detect if there's any meaningful uh clinical difference uh between two groups. Uh I would also definitely keep randomized double blind placebo control trial because that was one of the strengths of our study.

SPEAKER_02And also, as you know, the clinical uh GI science are variable and between different dogs. And as Jan said, also I think I will group dogs based on their baseline dysbiosis index and also their disease severity to determine whether we which dogs with which subgroup of dogs can benefit from FNT more than the others. And I would also, as Jan said, I would also compare uh oral versus NMR administration or combine them together at the same time and also comparing single versus repeated courses of on uh of of treatment and also a longer follow-up type.

SPEAKER_04That's a whole PhD's worth.

SPEAKER_02Yeah, I think so.

SPEAKER_04Yeah, you'll see things often like that's project, that's project, that's project. Keep you busy.

SPEAKER_02Well, there's a long road to go. That sounds like it.

SPEAKER_04That is thank you both so much for joining us today. We appreciate it.

SPEAKER_01Thank you so much.

SPEAKER_02Thank you so much for having us, and thank you so much for giving us this opportunity to discuss our job.

Sarah WrightFor our listeners and viewers, you can read Mosins and Yan's article in JAFMA. I'm Sarah Wright with Lisa Fordier. Be sure to tune in next week for another episode of Veterinary Vertex. And don't forget to leave us a rating and review, snap a podcast, or wherever you listen.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Beyond the Alcohol Swipe: Rapid Disinfection for Suture Scissors

    Nov 16, 202611 minAudio

    Send us Fan Mail A pair of suture scissors can feel like the definition of “low risk” until you look at what’s actually living on them between patients. We sit down with Kathryn P. Spivey, returning guest and AJVR...

    Credit the people on this episode

  2. Can a Nasal Vaccine Protect Calves From RSV?

    Nov 7, 202621 minAudio

    Send us Fan Mail A calf can look “fine” and still be losing ground in the lungs and that’s exactly why BRSV keeps costing farms money. We sit down with Dr. John Ellis to unpack a rare head-to-head comparison of two...

    Credit the people on this episode

  3. Hit or Miss: Antibiotic Delivery to Foal Joints

    Oct 23, 202617 minAudio

    Send us Fan Mail Septic arthritis in a neonatal foal is one of those diagnoses that can change everything fast: the foal’s comfort today, survival to discharge, and even long-term athletic soundness once cartilage gets...

    Credit the people on this episode

  4. Reading the Rhythm: How Cycle Length Variation Helps Diagnose Equine Arrhythmias

    Oct 17, 202616 minAudio

    Send us Fan Mail One strange beat on a resting horse ECG can spark a surprisingly high-stakes question: are we seeing a normal sinus arrhythmia, or an atrial premature complex that changes how we think about risk and...

    Credit the people on this episode

  5. Eye vs. Rectal Temperature in Dogs: A Diagnostic Comparison

    Oct 9, 202615 minAudio

    Send us Fan Mail A “normal temperature” can be the most dangerous kind of comforting. We sit down with Drs. Kimberly Woodruff and Sahar Rostami to unpack what happens when ocular thermometry and rectal thermometry show...

    Credit the people on this episode